General
Preferred name
PROBUCOL
Synonyms
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole ()
DH-581 ()
Probucol ()
Panavir ()
NSC-652160 ()
Sinlestal ()
Bisbid ()
NSC-86225 ()
Lurselle ()
Lorelco ()
P&D ID
PD001899
CAS
23288-49-5
Tags
natural product
drug
available
Approved by
FDA
First approval
1977
Drug Status
investigational
approved
withdrawn
Drug indication
Coronary artery disease
Antihyperlipidemic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Probucol is a lipid-lowering drug. Marketing of this drug was ceased in 1995 in the US due to safety concerns.
(GtoPdb)
MOA
Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. This drug may also act to inhibit the initial stages of cholesterol synthesis and act to inhibit the absorption of cholesterol from the diet. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux.
PHARMACODYNAMICS
Probucol lowers cholesterol levels by increasing LDL (low-density lipoprotein) breakdown. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption. Probucol is a powerful antioxidant drug normally used to prevent vascular disease caused by the free radicals in the body.
DESCRIPTION
Selective non-transportable GlyT1 inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Enhances selective uptake of HDL-associated cholesteryl esters.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
2
Compound Sets
32
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
516.31
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
9.91
TPSA
40.46
Fraction CSP3
0.61
Chiral centers
0.0
Largest ring
6.0
QED
0.31
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
ATP-binding cassette transporter blocker
Inhibitor
Antioxidants
ABCA1-mediated cellular lipid efflux inhibitor
Serine Protease Hepsin Inhibitors
atherogenesis inhibitor
Target
ATP-binding cassette sub-family A member 1
ABCA1
CES1
ABCA1, ABCB11, CES1
Virus Protease
LDL
Pathway
Membrane Transporter/Ion Channel
Metabolism
Anti-infection
Primary Target
Multidrug Transporters
Member status
member
Indication
coronary artery disease (CAD)
ATC
C10AX02
Therapeutic Class
Anticholesteremic Agents
Solubility
In vitro:<br/>10 mM in DMSO
Source data
